ArticleAntimicrobial agents and chemotherapy2017
A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis.
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Mathematical models of drug-resistant tuberculosis lack bacterial heterogeneity: A systematic review.PLoS pathogens · 2024Pooled it
- Estimating the health and macroeconomic burdens of tuberculosis in India, 2021-2040: A fully integrated modelling study.PLoS medicine · 2024Article
- Phenotypic and genotypic characterization ofFrontiers in microbiology · 2024Article
- Bayesian Calibration to Address the Challenge of Antimicrobial Resistance: A Review.IEEE access : practical innovations, open solutions · 2024Article
- Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis.Journal of clinical microbiology · 2022Article
- Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis using machine learning methods.PLOS digital health · 2022Article
- Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.BMC infectious diseases · 2020Article
- Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis.Antimicrobial agents and chemotherapy · 2018Article
- Dynamic model of tuberculosis considering multi-drug resistance and their applications.Infectious Disease Modelling · 2018Article
- Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?Antimicrobial agents and chemotherapy · 2018Article
- Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment.Antimicrobial agents and chemotherapy · 2017Article
- Reply to Anthony et al., "Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment".Antimicrobial agents and chemotherapy · 2017Article
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
Several infectious diseases of global importance-e.g., HIV infection and tuberculosis (TB)-require prolonged treatment with combination antimicrobial regimens typically involving high-potency core agents coupled with additional companion drugs that protect against the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.